Previous 10 | Next 10 |
EDISON, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH...
EDISON, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH...
EDISON, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH...
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- EquitiesIQ announced today that the EquitiesIQ Q4 2021 Investor Forum presentation, a virtual investor event series featuring Robert Foster, B.Sc. (Pharm), Pharm.D., Ph.D., Chief Executive Officer of Hepion Pharmaceuticals (NASDAQ: HEPA), has been...
NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) -- EquitiesIQ announced today that Robert Foster, B.Sc. (Pharm), Pharm.D., Ph.D., Chief Executive Officer of Hepion Pharmaceuticals (NASDAQ: HEPA), will present at the EquitiesIQ Q4 2021 Investor Forum, a virtual investor event series. Dr. Foster...
EDISON, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH...
EDISON, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NAS...
On September 13, Hepion Pharmaceuticals (NASDAQ:HEPA) reported additional data from phase IIa "AMBITION trial." The main data reported by the company was the % reduction of the Pro-C3 biomarker in serum. According to my estimate, CRV431 would be the candidate drug with the greates...
Itamar Medical (NASDAQ:ITMR) +44% on being taken over by Zoll Medical for ~$538M Leap Therapeutics (NASDAQ:LPTX) +42% to present new data from the DisTinGuish study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congres BELLUS Health (NASDAQ:BLU) +24% positive interim f...
Pro-C3 and ALT reductions point to anti-inflammatory and antifibrotic effects of CRV431 PK-PD models successfully predict early reductions in Pro-C3 and ALT Hepion’s proprietary AI-POWR™ and machine learning accurately predict CRV431 responders Anti...
News, Short Squeeze, Breakout and More Instantly...
Hepion Pharmaceuticals Inc. Company Name:
HEPA Stock Symbol:
NASDAQ Market:
Hepion Pharmaceuticals Inc. Website:
Gaucho Group Holdings Inc. (VINO) is expected to report for Q1 2024 Tosoh Corporation (TOSCF) is expected to report for Q4 2024 Adidas AG ADR - Level I (ADDYY) is expected to report $0.69 for Q1 2024 MicroCloud Hologram Inc. (HOLO) is expected to report for Q1 2024 Universal Enter...
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...
A look at the top 10 most actives in the United States AGBA Group Holding Limited (AGBA) rose 100.0% to $2.5 on volume of 201,539,290 shares PROSHARES TRUST (SQQQ) fell 2.9% to $12.47 on volume of 154,254,858 shares Tesla Inc. (TSLA) fell 3.4% to $142.05 on volume of 106,267,579 shares ...